Target intelligence / Profile preview

Gram-negative bacterial surface glycans (LPS/CPS)

Target
LPS/CPS
Molecular classification
Glycan, Glycolipid, Polysaccharide, Bacterial surface antigen
01

Overview

Gram-negative bacterial surface glycans are complex carbohydrate structures, including lipopolysaccharides (LPS), capsular polysaccharides (CPS), and O-antigens, that constitute the outermost layer of the bacterial cell envelope. These molecules are essential for maintaining the structural integrity of the outer membrane and serve as a critical barrier against detergents, host complement systems, and various antibiotics. LPS, in particular, is a potent pyrogen and the primary driver of the inflammatory cascade that leads to sepsis and septic shock when released into the bloodstream. Because these glycans often exhibit high species or strain specificity, they are primary targets for the development of conjugate vaccines and monoclonal antibodies aimed at narrow-spectrum antimicrobial therapy. Drugs targeting these epitopes typically work by neutralizing the toxic Lipid A component of LPS, disrupting membrane stability, or marking the bacteria for destruction by the host immune system.

Other names
LipopolysaccharideEndotoxinO-antigenCapsular polysaccharideBacterial surface carbohydratesOuter membrane glycansExopolysaccharide
02

Mechanism of action

Binding and neutralization of endotoxin, disruption of the bacterial outer membrane, opsonization for phagocytosis, and inhibition of bacterial adhesion to host cells.

03

Biological functions

Cell wall organizationImmune evasionPathogenesisPermeability barrierCell adhesionProtection from environmental stress
04

Disease associations

InfectionSepsisSeptic shockPneumoniaUrinary tract infection
05

Safety considerations

Jarisch-Herxheimer reactionEndotoxicity upon rapid bacterial lysisCross-reactivity with host glycansHigh antigenic variability leading to immune escape
06

Interacting drugs

Polymyxin B

5 more in the full profile.

07

Biomarkers

Endotoxin levelsAnti-O-antigen antibody titerProcalcitoninLimulus Amebocyte Lysate (LAL) reactivity

Beyond the preview

Go deeper on Gram-negative bacterial surface glycans (LPS/CPS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gram-negative bacterial surface glycans (LPS/CPS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call